Evaluation of the Efficacy of the Phyto-Drug Djovikas: Traditional Treatment against HIV Infection

Erick Ntambwe Kamangu1,2, Ben Ilunga Bulanda3, Berry Ikolango Bongenya2, Elvis Tshunza Kateba2,3, Medard Omakoy Okonda2, Victor Nyima Kasongo4, Michelline Abiba Kingombe3

1Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa-Democratic Republic of Congo
2"HIV/AIDS Focus" Research Group, Kinshasa - Democratic Republic of Congo
3National Program for the Promotion of Traditional Medicine and Medicinal Plants (PNMT-PM), Ministry of Public Health, Kinshasa-Democratic Republic of Congo
4Centre Tradi-moderne Bonkoko, Kinshasa-Democratic Republic of Congo

*Corresponding Author: Erick N. KAMANGU, Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa - Democratic Republic of Congo, Email: erick.kamangu@unikin.ac.cd

Abstract

Background: "Djovikas" is a phyto-drug based on local plants. It has been consumed for many years by a large number of people living with the Human Immunodeficiency Virus (PLHIV) in the city of Kinshasa and in other cities in the country.

Objective: The objective of this work was to evaluate the efficacy of the phyto-drug "Djovikas" 6 months after the beginning of the treatment of the patients.

Methods: Prospective cohort of 6 months on patients followed by traditional medicine. The participation in this work was voluntary. Ninety-seven (97) patients diagnosed with HIV-1 by serology were included in D0 at this work. All patients signed consent form for participation in the study. At the 6th month appointment, 48 patients returned for their clinical and biological evaluations. Clinical parameters were evaluated according to the WHO Clinical Stage classification for HIV infection. The biological parameters of the patients had been carried out in the same laboratories and under the same conditions.

Results: Out of 97 patients included in D0, 48 patients returned for their M6 appointment. This population was made up of 35 women and 13 men. The median age was of 41 years with extremes of 21 and 60 years. Forty-five patients (93.75%) were in Clinical Stage 2 according to WHO at the 6th month, followed by 3 patients (6.25%) in Clinical Stage 3. A Nested DNA PCR, to confirm the patient’s status, was positive in all patients. The median values of Viral Loads (VL) and CD4 lymphocyte count at month 6 were 1.56 log10RNA copies/ml (36.50 RNA copies/ml) and 456 cells/ml, respectively.

Conclusion: The phyto-drug "Djovikas" proved to be effective in the treatment of HIV infection. After 6 months of treatment, the patients’ VLs fell sharply and their immunity was restored after taking the drug.

Keywords: HIV, Djovikas, Phyto-drug, Efficiency, Kinshasa

Abbreviations


1. BACKGROUND

"Djovikas" is a phyto-drug (PD) based on local plants. It has been consumed for many years by a large number of People living with the Human Immunodeficiency Virus (PLHIV) in Kinshasa and in other neighboring cities [1].

In 2012, only 15% of people eligible for antiretroviral treatment (ART) currently had access to this treatment [1]. This situation had opened the door to finding alternative treatment for HIV infection by those patients who are the
first to be concerned in cases of insufficiency and out-of-stock of ART.

Tradi-modern medicine is already widely used in many African countries to fight HIV infection [2, 3, 4]. In Kinshasa, several works have demonstrated the effectiveness of plants and phyto-drugs against malaria [5], African Human Trypanosomiasis (AHT) [6] and other pathologies.

Nevertheless, there is no concrete data on the effectiveness of traditional medicine in the fight against HIV and AIDS in our environment. Hence the objective of this work was to evaluate the effectiveness of the phyto-drug "Djovikas" 6 months after the beginning of the treatment of the patients.

2. METHODS

2.1. Frame

The present work was a prospective 6-month cohort study on patients followed by traditional medicine. The inclusion period was from January 11th to March 11th, 2016.

2.2. Patients

Ninety-seven (97) patients diagnosed with HIV Type 1 by serology were included in D0 in this work. They were recruited voluntarily at the Bonkoko Tradi-Modern Center in Kinshasa. The inclusion criteria for the subjects were: (i) to be diagnosed HIV-1 positive according to national guidelines [7], (ii) to be over 18 years of age on the date of inclusion, and (iii) to be eligible for antiretroviral treatment (ART). Patient demographic, clinical and paraclinical information were recorded on the pre-tested survey forms for the study. Participation in this work was voluntary. All patients signed informed consent for participation in the study.

At the 6th month (M6) appointment, only 48 patients returned for their clinical and biological evaluations at the treatment center.

2.3. Tracking Settings

Age, sex, height, weight, and Body Mass Index (BMI) were the Anthropometric monitoring parameters that were assessed at baseline (D0), 1st, 3rd and 6th month (M1, M3 and M6) by clinicians. This information was recorded on individual patient files.

Clinical parameters were evaluated according to the World Health Organization (WHO) Clinical Stage classification for HIV infection [7]. These parameters were taken by the clinicians and recorded on the patient's individual files.

The biological parameters of the patients had been carried out in the same laboratories and under the same conditions for D0, M1, M3 and M6. The results of the analyzes were recorded on the patient's individual files. The biological parameters of interest were: CD4 count, Viral Load (VL), Amylase, urea, creatinine, blood glucose, total cholesterol, LDL, HDL, triglyceride, transaminases SGPT and SGOT.

2.4. Sampling and Analysis of Samples

At inclusion (D0) and at the 6th month (M6), 2 blood samples were taken from each patient from the elbow crease vein: one 5ml sample in one tube with EDTA anticoagulant and the other one 5ml with Lithium Heparin. The EDTA tube was used for CD4 count and VL while the Lithium tube was used for biochemistry analyzes (amylose, urea, creatinine, blood glucose, total cholesterol, LDL, HDL, triglyceride, SGPT transaminases and SGOT).

On D0, the Buffy coat taken from the EDTA tube was used to confirm the serological status of the patients using a Nested PCR previously described [8]. The VLs, as well as the confirmation PCRs, were carried out at the Molecular Biology Laboratory of the Faculty of Medicine of the University of Kinshasa (UNIKIN) using the specific techniques previously described [8,9]. While the biochemistry parameters were evaluated in the laboratory of Biochemistry of the Faculty of Pharmaceutical Sciences of UNIKIN.

3. RESULTS

Out of 97 patients included in D0, 48 patients returned for their M6 appointment. This population was made up of 35 women and 13 men. The median age was 41 years with extremes of 21 and 60 years. Forty-five patients (93.75%) were in Clinical Stage 2 according to WHO 6 month after starting treatment, followed by 3 patients (6.25%) in Clinical Stage 3.

Nested DNA PCR, to confirm the patient's status, was positive in all patients. The median values of VL and CD4 lymphocyte count at month 6 were 1.56 log_{10}RNA copies/ml (36.50 RNA copies/ml) and 456 cells/ml, respectively.

The results of the different biological analyzes carried out for M6 are presented in the following table 1.
Evaluation of the Efficacy of the Phyto-Drug Djovikas: Traditional Treatment against HIV Infection

Table 1. Paraclinical data of patients at the 6th month of treatment

<table>
<thead>
<tr>
<th>Biological Parameters</th>
<th>Median Values</th>
<th>Inclusion (D0)</th>
<th>∆</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycaemia (60-110 mg/dl)</td>
<td>85 ± 28.20</td>
<td>84.95 ± 19.08</td>
<td>+0.05</td>
</tr>
<tr>
<td>Urea (15-45 mg/dl)</td>
<td>28.84 ± 9.74</td>
<td>22.47 ± 6.66</td>
<td>+6.34</td>
</tr>
<tr>
<td>Creatinine (0.5-1.5 mg/dl)</td>
<td>1.09 ± 0.20</td>
<td>0.88 ± 0.26</td>
<td>+0.21</td>
</tr>
<tr>
<td>Cholesterol Total (110-200 mg/dl)</td>
<td>140.05 ± 37.42</td>
<td>169.60 ± 37.74</td>
<td>-29.55</td>
</tr>
<tr>
<td>Cholesterol HDL (30-70 mg/dl)</td>
<td>38.70 ± 11.30</td>
<td>52.75 ± 15.13</td>
<td>-13.90</td>
</tr>
<tr>
<td>Cholesterol LDL (&lt;160 mg/dl)</td>
<td>77.34 ± 29.34</td>
<td>96.4 ± 31.45</td>
<td>-19.06</td>
</tr>
<tr>
<td>Triglyceride (35-185 mg/dl)</td>
<td>109.5 ± 33.83</td>
<td>102.8 ± 46.92</td>
<td>+6.70</td>
</tr>
<tr>
<td>Transaminase SGPT (0-31 IU/L)</td>
<td>37.62 ± 15.46</td>
<td>23.35 ± 11.11</td>
<td>+14.32</td>
</tr>
<tr>
<td>Transaminase SGOT (0-41 IU/L)</td>
<td>30.2 ± 15.09</td>
<td>22.34 ± 10.85</td>
<td>+7.90</td>
</tr>
<tr>
<td>Amylase (0-95 IU/L)</td>
<td>89.74 ± 39.04</td>
<td>81.89 ± 31.14</td>
<td>+7.84</td>
</tr>
</tbody>
</table>

+ = increase in values compared to D0; - = decrease in values compared to D0.

4. DISCUSSION

The objective of this work was to determine the efficacy of the phyto-drug "Djovikas" as traditional treatment against HIV infection used in Kinshasa.

Out of 97 patients included in D0, 48 patients returned for their 6th month appointment. This population was made up of 35 women and 13 men. The loss rate of the patients was 50.5% compared to the total number of patients at the beginning of treatment. The losses of patients were generally attributed to the loss of sight in the centers but also because of deaths in outpatient treatment centers (ATC) for the monitoring of People Living with HIV (PLHIV) in our environment [10]. In this work, beyond known reasons, perditions can also be caused by the society and its lack of adherence to traditional medicine [2].

After 6 months of treatment, 45 patients (93.75%) were in Clinical Stage 2 according to the WHO and 3 patients (6.25%) in Clinical Stage 3. No patients evolved into Clinical Stage 4. Compared with patient's data at the inclusion [11], patients' health status did not deteriorate using traditional treatment with "Djovikas". From a clinical point of view, this drug is well tolerated by patients and has not caused any failure.

The main goal of Anti Retro Viral (ART) therapy is to suppress viral replication or reduce plasma VL by making it undetectable, and restore patient immunity which results in increased T4 lymphocytes (CD4). After 6 of treatment with "Djovikas", the median values of VLs and CD4 Lymphocyte levels were respectively 1.56 log_{10}RNA copies/ml (36.50 RNA copies/ml) and 456 cells/ml. At inclusion, the median VL and CD4 values were 4.10 log_{10}RNA copies/ml and 220 cells/ml, respectively [11]. These results show a clear improvement in the state of health of patients taking the phyto-drug.

The results of the different biological analyzes carried out for M6 were presented in the table 1. All average values obtained are in the limits of the parameters (Blood glucose: 85 ± 28.20 mg/dl, Urea: 28.84 ± 9.74 mg/dl, Creatinine: 1.09 ± 0.20 mg/dl, Total cholesterol: 140.05 ± 37.42 mg/dl, HDL cholesterol: 38.70 ± 11.30 mg/dl, LDL cholesterol: 77.34 ± 29.34 mg/dl, Triglyceride: 109.5 ± 33.83 mg/dl, SGPT Transaminase: 37.62 ± 15.46 IU/L, SGOT Transaminase: 30.2 ± 15.09 IU/L, Amylase: 89.74 ± 39.04 IU/L). Compared to the mean values recorded in D0 [11], there was a clear, though not significant, increase in urea (Δ = 6.34 mg/dl), creatinine (Δ = 0.21 mg/dl), triglyceride (Δ = 6.7 mg/dl), SGPT (Δ = 14.32 IU/L), SGOT (Δ = 7.9 IU/L) and amyylase (Δ = 7.84 IU/L); and a remarkable decrease in total cholesterol (Δ = -29.55 mg/dl), HDL (Δ = -13.9 mg/dl) and LDL (Δ = -19.06 mg/dl).

5. CONCLUSION

The phyto-drug "Djovikas" proved to be effective in the treatment of HIV infection in our environment. After 6 months of treatment, the patients' VLs decrease sharply and their immunity was restored after taking the phyto-drug compared to the start of treatment.

6. AUTHORS’ CONTRIBUTION

ENK, BIB¹, BIB², ETK and MAK conceived and designed the study. ENK, BIB¹, BIB², ETK, MOO and VNK acquired the data. ENK, BIB¹, BIB², ETK and MOO analyzed and interpreted the data. ENK, BIB1, BIB2 and ETK drafted the manuscript. ENK, BIB¹, BIB², ETK, MOO and MAK revised the manuscript. ENK, BIB¹, BIB², ETK and MOO approved the final version of the manuscript.
manuscript. All authors read and approved the final manuscript.

REFERENCES


